Ligand Pharmaceuticals to Acquire XOMA Royalty for $739 Million to Boost Portfolio

In a strategic move to strengthen its position within the biotech royalty sector, Ligand Pharmaceuticals has entered into a definitive agreement to acquire XOMA Royalty for approximately $739 million. Under the terms, XOMA shareholders will receive $39.00 per share in cash, alongside a Contingent Value Right (CVR) entitling them to 75% of net proceeds from certain pending litigation. The transaction is slated to close in the third quarter of 2026 and is expected to be immediately accretive to LGND earnings per share.

This acquisition occurs amid a broader trend of consolidation in the pharmaceutical royalty space, as firms seek stable cash flows to hedge against R&D volatility. Compared to recent activity by peers like Royalty Pharma, Ligand’s move specifically targets a diversified portfolio of milestone-driven assets. Per market data, the cash premium offered aligns with recent sector valuations for high-margin royalty aggregators, reflecting management's confidence in XOMA’s underlying asset base.

Investors are now focused on the integration timeline and the potential upside from the CVR linked to legal outcomes. While the deal is not expected to close until Q3 2026, market participants will monitor upcoming US economic data, including CPI releases, for insights into the broader financing environment. The focus remains on LGND's ability to maintain its growth trajectory as it incorporates XOMA’s assets into its existing royalty infrastructure.